Identification of Human Autologous Cytotoxic T-Lymphocyte-Defined Osteosarcoma Gene That Encodes a Transcriptional Regulator, Papillomavirus Binding Factor

• Tomohide Tsukahara

  1Departments of Orthopedic Surgery and

• Yuki Nabeta

  1Departments of Orthopedic Surgery and

• Satoshi Kawaguchi

  1Departments of Orthopedic Surgery and

• Hideyuki Ikeda

  3Division of Clinical Pathology, Sapporo Medical University, Sapporo, Japan;

• Yuriko Sato

  1Departments of Orthopedic Surgery and

• Kumiko Shimozawa

  4Cancer Vaccine Laboratory, Japan Science and Technology Corporation, Sapporo, Japan; and

• Kazunori Ida

  1Departments of Orthopedic Surgery and

• Hiroko Asanuma

  3Division of Clinical Pathology, Sapporo Medical University, Sapporo, Japan;

• Yoshihiko Hirohashi

  2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan;

• Toshihiko Torigoe

  2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan;

• Hiroaki Hiraga

  5Department of Clinical Research, Division of Orthopedics, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan

• Satoshi Nagoya

  1Departments of Orthopedic Surgery and

• Takuro Wada

  1Departments of Orthopedic Surgery and

• Toshihiko Yamashita

  1Departments of Orthopedic Surgery and

• Noriyuki Sato

  2Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan;

抄録

The prognosis for patients with osteosarcoma who do not respond to current chemotherapy protocols still remains poor. Toward the goal of establishing efficacious peptide-based immunotherapy for those patients, we previously developed an autologous pair of CTLs and an osteosarcoma cell line. In the current study, we screened the cDNA library of this osteosarcoma cell line using an autologous CTL clone and identified cDNA encoding an antigen. The isolated cDNA was identical to papillomavirus binding factor (PBF), which was recently reported as a DNA binding transcription factor cooperating with RUNX1. Reverse transcription-PCR analysis revealed that PBF was expressed in 16 of 19 cases of bone and soft-tissue sarcoma cell lines (5 of 6 of osteosarcoma lines) and 57 of 76 sarcoma tissue samples (11 of 14 of osteosarcoma tissues). Also, PBF was expressed in 10 of 13 epithelial cancer cell lines and 20 of 34 of cancer tissues. In contrast, PBF was detected in some normal organs including ovary, pancreas, spleen, and liver by reverse transcription-PCR but was restricted in the cytoplasm by immunostaining and undetectable by Western blotting. Furthermore, a 12-mer peptide, CTACRWKKACQR, located at the COOH terminus of PBF, was found to be a minimum requirement for recognition by the CTL clone in the context of the HLA-B*5502 molecule. These findings suggest that PBF is a shared tumor-associated antigen, which may serve as a source of peptides applicable to peptide-based immunotherapy for osteosarcoma and other malignant tumors.

収録刊行物

• Cancer Research

  Cancer Research 64 (15), 5442-5448, 2004-08-01

  American Association for Cancer Research (AACR)

キーワード

• Cancer Research
• Oncology

詳細情報

• CRID: 1362262944858626944
• NII論文ID: 30018590215
• DOI: 10.1158/0008-5472.can-04-0522
• ISSN: 15387445
• ISSN: 00085472
• ISSN: http://id.crossref.org/issn/00085472
• Web Site: https://aacrjournals.org/cancerres/article-pdf/64/15/5442/2517498/5442.pdf
• データソース種別:
  • Crossref
  • CiNii Articles